Breaking News Instant updates and real-time market news.

KFY

Korn/Ferry

$30.46

-0.1498 (-0.49%)

, GSK

GlaxoSmithKline

$41.50

0.16 (0.39%)

13:44
02/21/17
02/21
13:44
02/21/17
13:44

Korn Ferry Futurestep partners with GlaxoSmithKline over talent acquisition

Futurestep division of Korn Ferry (KFY) has been appointed by GlaxoSmithKline (GSK) to provide a Flexible Delivery Solution for recruitment support across the United Kingdom, United States and Latin America. In a desire to better respond to business requirements and to help prepare for future recruitment demand, GSK chose Futurestep to assist with hiring across its Pharmaceutical, Consumer Healthcare and Vaccines business units. Futurestep will deploy a dedicated onsite team of specialist recruiters across key locations. This will be complemented by dedicated sourcing and screening hubs within Futurestep's Warsaw, Manchester, Bangalore and Dallas Talent Delivery Centres.

KFY

Korn/Ferry

$30.46

-0.1498 (-0.49%)

GSK

GlaxoSmithKline

$41.50

0.16 (0.39%)

  • 21

    Feb

KFY Korn/Ferry
$30.46

-0.1498 (-0.49%)

08/17/16
DBAB
08/17/16
INITIATION
Target $27
DBAB
Hold
Korn/Ferry initiated with a Hold at Deutsche Bank
Target $27.
08/18/16
08/18/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Barnes & Noble (BKS) initiated with a Neutral at Sidoti. 2. Digital Ally (DGLY) initiated with a Buy at Maxim. 3. Korn/Ferry (KFY) initiated with a Hold at Deutsche Bank. 4. Phillips 66 Partners (PSXP) initiated with a Buy at Stifel. 5. Arrowhead (ARWR) initiated with a Buy at Cantor. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
09/09/16
RHCO
09/09/16
NO CHANGE
RHCO
Korn/Ferry showing signs of rebounding, says SunTrust
After Korn/Ferry reported slightly higher than expected Q2 revenue but slightly lower than expected EPS, SunTrust analyst Tobey Sommer says there are signs that demand for the company's services is rebounding. The analyst says that the company's Executive Search unit obtained 25% more new business in North America in August versus July. Sommer expects the company's Futurestep business to remain strong throughout this year. The analyst reiterates a Buy rating on the stock.
02/15/17
RHCO
02/15/17
NO CHANGE
RHCO
Korn/Ferry shares should be bought at current levels, says SunTrust
SunTrust analyst Tobey Sommer says a survey of private executive search firms indicates that their sentiment is improving. Additionally, the analyst remains upbeat on KornFerry's Futurestep business, and Sommer keeps a $34 price target and a Buy rating on the stock.
GSK GlaxoSmithKline
$41.50

0.16 (0.39%)

10/03/16
RBCM
10/03/16
NO CHANGE
Target $95
RBCM
Outperform
Gilead HIV franchise could see risk from competitor data, says RBC Capital
RBC Capital analyst Michael Yee said his conversations with doctors leads him to think two dolutegravir HIV "doublet" studies being conducted by GlaxoSmithKline (GSK) and ViiV Healthcare - Glaxo's joint venture with Pfizer (PFE) and Shionogi - are likely to work and present an underappreciated risk to Gilead's (GILD) HIV franchise. Talks with investors lead Yee to believe few are even aware of this risk and that the consensus view is underestimating the probability these non-inferiority trials will work. Arguing that the consensus view should factor in more conservative assumptions for Gilead's HIV business post 2018 due to this risk, Yee cut his price target on Gilead to $95 from $105, but keeps an Outperform rating on the shares.
10/06/16
PIPR
10/06/16
NO CHANGE
Target $46
PIPR
Overweight
Piper thinks Alnylam failure is positive for Ionis
Piper Jaffay analyst Joshua Schimmer thinks Alnylam Pharmaceuticals' (ALNY) "abrupt halt" of revusiran for TTR cardiomyopathy is likely a positive for Ionis Pharmaceuticals' (IONS) transthyretin program. The move "knocks out a competitive drug" while Ionis and GlaxoSmithKline (GSK) remain on their previously indicated timeline, Schimmer tells investors in a research note. The analyst at this point believes Alnylam's setback will be limited to revusiran and not read-through to other Gal-Nac programs or other TTR cardiomyopathy or polyneuropathy programs. He keeps an Overweight rating on Ionis with a $46 price target,
11/09/16
SBSH
11/09/16
NO CHANGE
SBSH
Citi sees Healthcare 'relief rally' after Trump win
Citi analyst Andrew Baum expects a "'relief rally" to drive near-term sector outperformance for names in the Healthcare space given the "inability of the Democrats to attain the Presidency, the House or Congress." Longer term, however, the analyst still sees "significant continued legislative risk" for pharma reimbursement. Baum prefers GlaxoSmithKline (GSK), AstraZeneca (AZN), Shire (SHPG) and Roche (RHHBY) among European majors and Bristol-Myers (BMY) and Eli Lilly (LLY) in the U.S.
02/14/17
RBCM
02/14/17
NO CHANGE
RBCM
Gilead data better than expected, says RBC Capital
RBC Capital analyst Michael Yee says that data on Gilead's (GILD) HIV treatment, bictegravir, shows that the drug was more effective than GlaxoSmithKline's (GSK) dolutegravir in treatment-naive HIV patients. The analyst thinks that the data indicates that Gilead's HIV franchise should be valued at $50+ per share, although he warns that data on a GlaxoSmithKline treatment due to next year could pose a threat to Gilead. He keeps an Outperform rating on Gilead.

TODAY'S FREE FLY STORIES

RBGLY

Reckitt Benckiser

$20.53

0.04 (0.20%)

, MJN

Mead Johnson

$89.29

0.1 (0.11%)

15:32
05/28/17
05/28
15:32
05/28/17
15:32
Conference/Events
Mead Johnson to host special shareholder meeting »

Special Shareholder…

RBGLY

Reckitt Benckiser

$20.53

0.04 (0.20%)

MJN

Mead Johnson

$89.29

0.1 (0.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

PHH

PHH Corp.

$13.58

0.06 (0.44%)

15:25
05/28/17
05/28
15:25
05/28/17
15:25
Conference/Events
PHH Corp. to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

TPIV

TapImmune

$3.71

-0.03 (-0.80%)

14:37
05/28/17
05/28
14:37
05/28/17
14:37
Conference/Events
TapImmune to hold a business update conference call »

Management holds a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

SCOR

comScore

$24.80

-0.15 (-0.60%)

14:35
05/28/17
05/28
14:35
05/28/17
14:35
Conference/Events
comScore to host business news update conference call »

Management holds a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

BMY

Bristol-Myers

$53.97

-0.42 (-0.77%)

14:12
05/28/17
05/28
14:12
05/28/17
14:12
Conference/Events
Bristol-Myers to hold a pharmaceutical update conference call »

Management provides an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Jun

  • 04

    Jun

  • 06

    Jun

  • 24

    Sep

LOXO

Loxo Oncology

$47.44

-0.06 (-0.13%)

14:10
05/28/17
05/28
14:10
05/28/17
14:10
Conference/Events
Loxo Oncology to hold a pharmaceutical update conference call »

Management discusses the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Jun

  • 04

    Jun

  • 06

    Jun

ADRO

Aduro Biotech

$10.05

-0.15 (-1.47%)

14:07
05/28/17
05/28
14:07
05/28/17
14:07
Conference/Events
Aduro Biotech to host analyst and investor meeting »

Management hosts special…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Jun

ELGX

Endologix

$4.73

-0.05 (-1.05%)

14:06
05/28/17
05/28
14:06
05/28/17
14:06
Conference/Events
Endologix to hold a pharmaceutical update conference call »

Management discusses the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

  • 31

    May

  • 03

    Jun

TSRO

Tesaro

$149.11

-4.08 (-2.66%)

14:02
05/28/17
05/28
14:02
05/28/17
14:02
Conference/Events
Tesaro to hold an analyst and investor briefing »

Management hosts an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Jun

  • 03

    Jun

  • 30

    Jun

ICE

IntercontinentalExchange

$60.35

-0.09 (-0.15%)

13:57
05/28/17
05/28
13:57
05/28/17
13:57
Conference/Events
IntercontinentalExchange to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Jun

  • 07

    Jun

CPA

Copa Holdings

$111.69

0.2 (0.18%)

13:48
05/28/17
05/28
13:48
05/28/17
13:48
Conference/Events
Copa Holdings to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Jun

CAH

Cardinal Health

$73.10

-0.34 (-0.46%)

13:31
05/28/17
05/28
13:31
05/28/17
13:31
Conference/Events
Cardinal Health to hold a meeting »

Dublin Day to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Jun

BPMX

BioPharmX

$0.64

0.0089 (1.41%)

13:26
05/28/17
05/28
13:26
05/28/17
13:26
Conference/Events
BioPharmX holds state of acne symposium »

Management provides…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVS

Novartis

$80.63

-0.72 (-0.89%)

13:20
05/28/17
05/28
13:20
05/28/17
13:20
Conference/Events
Novartis to hold a meeting »

Meet the Management Day…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Jun

  • 26

    Jun

CNC

Centene

$74.57

-0.68 (-0.90%)

, MOH

Molina Healthcare

$66.87

-0.21 (-0.31%)

12:34
05/27/17
05/27
12:34
05/27/17
12:34
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

CNC

Centene

$74.57

-0.68 (-0.90%)

MOH

Molina Healthcare

$66.87

-0.21 (-0.31%)

HUM

Humana

$232.25

0.02 (0.01%)

AET

Aetna

$145.57

0.34 (0.23%)

ANTM

Anthem

$183.08

1.58 (0.87%)

UNH

UnitedHealth

$177.50

-0.55 (-0.31%)

WCG

WellCare

$172.97

0.15 (0.09%)

CI

Cigna

$161.32

-0.33 (-0.20%)

BX

Blackstone

$32.58

0.11 (0.34%)

NUE

Nucor

$58.15

-0.22 (-0.38%)

X

U.S. Steel

$19.74

-0.51 (-2.52%)

STLD

Steel Dynamics

$33.71

-0.73 (-2.12%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

  • 13

    Jun

  • 16

    Jun

21:00
05/26/17
05/26
21:00
05/26/17
21:00
General news
Breaking General news story  »

San Francisco Federal…

20:00
05/26/17
05/26
20:00
05/26/17
20:00
General news
Breaking General news story  »

San Francisco Federal…

JUNO

Juno Therapeutics

$23.30

-2.22 (-8.70%)

18:11
05/26/17
05/26
18:11
05/26/17
18:11
Hot Stocks
Juno Therapeutics director acquires 20,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Jun

UNH

UnitedHealth

$177.50

-0.55 (-0.31%)

18:06
05/26/17
05/26
18:06
05/26/17
18:06
Hot Stocks
UnitedHealth's OptumHealth awarded $200.5M government contract »

UnitedHealth's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

VEC

Vectrus

$29.62

0.02 (0.07%)

17:56
05/26/17
05/26
17:56
05/26/17
17:56
Hot Stocks
Vectrus Systems awarded $212.03M modification to government contract »

Vectrus Systems was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IMMY

Imprimis

$3.34

-0.06 (-1.76%)

17:52
05/26/17
05/26
17:52
05/26/17
17:52
Syndicate
Breaking Syndicate news story on Imprimis »

Imprimis files $75M mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IRCP

IRSA Propiedades Comerciales

$43.58

-0.33 (-0.75%)

17:51
05/26/17
05/26
17:51
05/26/17
17:51
Syndicate
Breaking Syndicate news story on IRSA Propiedades Comerciales »

IRSA Propiedades…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DSKE

Daseke

$9.79

-0.11 (-1.11%)

17:44
05/26/17
05/26
17:44
05/26/17
17:44
Syndicate
Breaking Syndicate news story on Daseke »

Daseke files $300M mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ECYT

Endocyte

$2.47

0.02 (0.82%)

, RNN

Rexahn

$4.04

0.09 (2.28%)

17:35
05/26/17
05/26
17:35
05/26/17
17:35
Hot Stocks
On The Fly: After Hours Movers »

HIGHER: Endocyte (ECYT),…

ECYT

Endocyte

$2.47

0.02 (0.82%)

RNN

Rexahn

$4.04

0.09 (2.28%)

TGTX

TG Therapeutics

$12.05

0.15 (1.26%)

SGMO

Sangamo

$7.25

-0.55 (-7.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Jun

  • 05

    Jun

  • 05

    Jun

  • 06

    Jun

  • 22

    Jun

ECYT

Endocyte

$2.47

0.02 (0.82%)

17:33
05/26/17
05/26
17:33
05/26/17
17:33
Hot Stocks
Endocyte to announce updated data on EC1456, EC1169 at ASCO »

Endocyte announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.